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A B S T R A C T
The majority of α-synuclein (α-syn) within Lewy bodies (LBs) has been reported to be phosphorylated at serine
129 (pS129-α-syn), suggesting a central role for phosphorylation in the pathogenesis of Parkinson’s disease (PD)
and related synucleinopathies. Various studies have investigated the effect of α-syn phosphorylation but have
failed to reach a consensus as to whether this modification accelerates or inhibits α-syn aggregation.
Nevertheless, pS129-α-syn is a reliable marker of α-syn aggregates and is widely evaluated in biomarkers and
post-mortem studies. While several antibodies specific for pS129-α-syn exist, their reactivity with non-specific
antigens appears to be a common challenge. To gain valuable insights into the role of α-syn phosphorylation in
disease pathogenesis, antibodies that are highly specific to pS129-α-syn are necessary. In this study, we describe
the generation of three mouse monoclonal antibodies (mAbs; 5B9, 6H5 and 9G1) using hybridoma technology.
These were thoroughly characterized and validated in combination with our previously generated mAb (PS129),
and the commercial ab51253 (Abcam). We demonstrated that our mAbs are highly specific for pS129-α-syn and
do not cross react with wild-type α-syn. Results from staining of post-mortem human brain tissue showed that our
mAbs detect pS129-α-syn pathology in patients with synucleinopathies. This study highlights three new anti-
bodies as excellent and highly specific research tools to explore the role of pS129-α-syn inclusions in synu-
cleinopathies.
1. Introduction
Over the past two decades, mounting evidence from genetic, pa-
thological and biochemical studies suggested a central role for α-sy-
nuclein (α-syn) in the pathogenesis of several neurodegenerative dis-
orders. These are collectively termed synucleinopathies and mainly
include Parkinson's disease (PD), dementia with Lewy bodies (DLB),
and multiple system atrophy (MSA). Synucleinopathies are character-
ized by the presence of protein-rich inclusions which are mainly com-
posed of α-syn aggregates [1]. These inclusions can occur within
neurons in the form of Lewy bodies (LBs), Lewy neurites (LNs), and also
within oligodendrocytes as glial cytoplasmic inclusions (GCIs) [1]. In-
creasing number of studies indicate that α-syn within LBs is subject to
various post-translational modifications (PTMs) such as phosphoryla-
tion, nitration, ubiquitination, and truncation, and these may con-
tribute to the regulation of α-syn aggregation and toxicity in disease
pathology [2]. Among these PTMs, phosphorylation of α-syn at serine
129 (pS129-α-syn) has been studied the most. This is because the ma-
jority of α-syn accumulated in LBs, LNs, or GCIs is phosphorylated at
S129 whereas minimal phosphorylation takes place under normal
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physiological conditions [3]. Given its pathological relevance, anti-
bodies against pS129-α-syn have been long used to reliably assess α-syn
pathology in brain sections from patients with synucleinopathies [4,5].
There is a continued debate about the role of phosphorylation in the
initiation of α-syn aggregation [3]. While some studies identified S129
phosphorylation as an early event that accelerates α-syn aggregation
and toxicity [6,7], other studies have shown that it acts as a protective
mechanism against neurotoxicity [8–10]. Despite intensive research,
the role of phosphorylation and the stage at which it takes place still
remains unclear. Given the abundance of pS129-α-syn as a primary
component of α-syn inclusions and our limited understanding of its role
in α-syn pathology, it is of great importance to generate reliable tools
with high specificity against pS129-α-syn. Development of such anti-
bodies has been a challenge and most existing pS129-α-syn monoclonal
antibodies (mAbs) cross-react with other proteins, such as neurofila-
ment protein [11,13,14]. Here we describe the generation and ex-
tensive characterization of new mAbs that are highly specific for pS129-
α-syn. We highlight the potential usefulness of our antibodies in dis-
secting the role of α-syn phosphorylation in synucleinopathies.
2. Materials and methods
2.1. Immunization
We used a short synthetic peptide, designed over the region of in-
terest (a.a. 125–133; CYEMPS(p)EEGY; (p) is a phosphate group). The
peptide was solubilized in phosphate-buffered saline (PBS) and con-
jugated to KLH. Experimental procedures using mice were carried out
in accordance with Laboratory Animal Research Center (LARC), Qatar
University (QU), Qatar, according to the QU institutional ethical rules
and regulations and approved by QU—IACUC & IBC. BALB/c female
mice (6–8 weeks old) were injected subcutaneously with the im-
munogen mixture. 10 days post booster immunization, blood was col-
lected from the tail vain and titer response was evaluated using indirect
ELISA. Mice exhibiting a strong immune response were subjected to a
final immunization before euthanization.
2.2. Indirect ELISA to evaluate immune response of the host
A 96-well clear plate was coated with recombinant WT- or pS129- α-
syn and incubated overnight at 4 °C. The following day, the plate was
blocked with blocking buffer (PBST containing 2.25 % gelatin) for 1 h
at RT. The plate was then washed three times with PBST, and antisera
from the mice were added in serial dilutions. Next, the plate was wa-
shed and goat anti-mouse IgG-HRP (1:20 K, Jackson) was added. The
plate was washed again and detected with TMB substrate (Abcam).
Following color development, the reaction was stopped by addition of
0.6 N H2SO4 and the absorbance was measured at 450 nm using Perkin-
Elmer atomic absorption spectrometer.
2.3. Generation of mouse hybridoma
Splenocytes were fused with mouse myeloma cells (Sp2O-Ag14;
American Type Culture Collection) at a ratio of 5:1 and fusion was
induced using 50 % polyethylene glycol. Fused cells were seeded in 96-
well plate in IMDM media (Gibco) containing HAT (Sigma), as pre-
viously described [26].
2.4. Isotyping and mass culture of positive clones
Positive clones were transferred to 24-well plate and screened
multiple times to ensure stability. For isotyping, culture supernatant
was screened against anti-mouse heavy chain antibodies (Isotyping Kit,
Sigma) in ELISA and only IgG-positive clones were selected. Those were
subjected to single-cell cloning. Wells with single clones were grown to
confluency and screened at least three times for further selection of
stable clones. Selected clones were grown in CDM4mAb media
(Hyclone) to confluency. Culture supernatant was then collected and
purified using protein-G agarose affinity chromatography (Sigma-
Aldrich, USA). Several mAbs were produced, purified and extensively
characterized, among which 5B9, 6H5, and 9G1 were selected for this
study.
2.5. Recombinant α-syn expression and purification
Expression and purification of recombinant human α-syn was per-
formed as previously described [38]. Briefly, human α-syn cDNA was
cloned into a pRK172 vector and transformed into BL21(DE3) E. coli for
protein expression. Protein expression was carried out in TB medium
and incubated over night at 37 °C. Cells were lysed using high salt
buffer (750mM Tris pH 7.6, 1 mM EDTA, 1mM PMSF, 1000X cocktail
protease inhibitors). For purification, lysates were passed through the
gel filtration column twice using ÄKTAxpress system.
2.6. In vitro phosphorylation of recombinant α-syn
Recombinant human α-syn (180 μM) was phosphorylated by in-
cubation with PLK2 enzyme (Invitrogen). The phosphorylation reaction
was carried out in the presence of 1.09mM ATP (Sigma), 1X reaction
solution (20mM HEPES, 10mMMgCl2, 2 mM DDT, pH 7.4), and 1 μg of
PLK2 at 37 °C for 24 h.
2.7. Western blot
50 ng of recombinant human proteins and 10 μg of human brain
lysates were separated on 15 % SDS-PAGE gels. Samples of urea-soluble
human brain lysates were prepared as previously described [15]. The
gels were then transferred to 0.45 μm nitrocellulose membranes. The
membranes were blocked with 5% BSA and incubated with the anti-
bodies at 100 ng/ml. Secondary antibody was added at 1:20 K dilution.
Immunoreactive bands were visualized using the SuperSignal West Pico
Chemiluminescent Substrate Kit.
2.8. Indirect ELISA for affinity estimation
Similar to the protocol described in Section 2.3, a 384-well black
plate (Nunc) was coated with WT- or pS129 α-syn monomers. These
were detected by our purified mAbs (5B9, 6H5, or 9G1) in serial dilu-
tions. Goat anti-mouse secondary antibody was added and enhanced
chemiluminescent substrate (Super Signal ELISA Femto, Pierce Bio-
technology) was used for detection. The chemiluminescence, expressed
in relative light units, was immediately measured using Perkin-Elmer
atomic absorption spectrometer.
2.9. Slot blot
Slot blot was performed using a Minifold 48 slots (GE Healthcare
Life Sciences, PR 648). 50 μL of each protein sample was loaded into
each slot on a nitrocellulose membrane that has been pre-soaked in PBS.
Proteins were loaded at a final concentration of 1 μg/ml. Samples were
allowed to adsorb onto the nitrocellulose membrane and then slots were
washed with 1ml of PBS. Remaining steps were performed as pre-
viously described for western blotting (Section 2.7).
2.10. Immunohistochemistry
We obtained 6 μm formalin-fixed paraffin-embedded post-mortem
human brain tissue from the substantia nigra of a PD case, amygdala
from a DLB case, entorhinal cortex from a mixed DLB/AD case and
putamen of an MSA case for immunohistochemical staining. Optimal
epitope unmasking was empirically determined, with heat-mediated
antigen retrieval in boiling citrate pH6 followed by five minutes in
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formic acid found to confer a modestly better signal compared to EDTA
pH8 and citrate pH6 without formic acid for all antibodies.
Immunohistochemical staining was conducted using the Menarini
MenaPath X-Cell Plus HRP detection kit (Menarini Diagnostics,
Berkshire), according to manufacturer’s instructions, before slides were
counterstained in hematoxylin and mounted using DPX (CellPath,
Powys). Immunopositivity was visualized using a Nikon Eclipse 90i
microscope with DsFi1 camera.
3. Results
3.1. Generation of mAbs specific for pS129-α-syn
In order to generate mAbs specific for pS129-α-syn, we immunized
female Balb/C mice with phosphopeptide-S129 (CYEMpSEEGY - α-syn
125–133) subcutaneously. All mice exhibited a high antibody titer after
repeated immunization. Following fusion, 900 clones were cultured in
96-well plates. Initial screening identified 124 positive hybridoma,
which were screened for their specificity towards pS129-α-syn. Using
indirect ELISA, we identified 57 positive clones that were reactive to
pS129-α-syn (Fig. 1A). These were further screened and only clones
that did not cross-react with WT-α-syn were transferred to 24-well
plate. Based on these criteria, a total of 20 clones were selected
(Fig. 1B).
Next, we performed isotyping analysis of the antibodies produced
and short-listed six clones that produced IgG antibodies, whereas the
remaining clones producing IgM-class antibodies, or a mixed isotype
were excluded. Parental IgG-secreting clones were then passaged mul-
tiple times and three clones with highest stability were subjected to
single cell cloning. Culture supernatant from wells containing single
colonies was re-tested for specificity, stability and the isotypes were
confirmed. Three single clones exhibiting the highest affinity towards
pS129-α-syn were selected for this study, namely 5B9, 6H5, and 9G1.
Their isotypes were identified as: 5B9 (IgG2a) 6H5 (IgG1) and 9G1
(IgG2a) (Fig. 1C).
The epitopes for these antibodies were mapped using alanine
scanning. Epitopes of 5B9 and 6H5 map to amino acids 128–131,
whereas 9G1 recognizes amino acids 126–129, and PS129 maps to
amino acids 124–129 (Fayyad et al., submitted for publication else-
where). Based on these epitopes, our three newly generated antibodies
can recognize pS129-α-syn if it is also phosphorylated at tyrosine 125
and/or tyrosine 133. PS129 however cannot as Y125 falls within its
epitope (i.e. a phosphate group would disrupt recognition). This di-
versity in the epitopes makes these antibodies valuable research tools to
explore the role of phosphorylation in α-syn pathology.
3.2. Assessing the specificity of the antibodies towards pS129-α-syn
Following purification of the mAbs using protein-G agarose chro-
matography, the purity was ensured using SDS-PAGE (Fig. 2A). Next,
we sought to assess their specificity towards pS129-α-syn. Recombinant
wild-type α-syn (WT-α-syn) or pS129-α-syn proteins were probed with
5B9, 6H5, and 9G1. Western blotting analysis showed that the 3 mAbs
are highly specific towards pS129-α-syn and do not cross-react with
WT-α-syn (Fig. 2B). Our in-house mAb PS129 specific for pS129-α-syn
[14], as well as the commercial mAbs ab51253 (also called EP1536Y;
Abcam) for pS129-α-syn and Syn-1 (BD Biosciences) for total α-syn,
were included as controls (Fig. 2B).
Fig. 1. Screening of positive hybridoma clones for generation of pS129-α-syn mAbs. (A) Reactivity of culture supernatant from a total of 124 hybridoma clones
towards pS129-α-syn. Optical density at 450 nm was measured and 57 clones with OD≥ 0.5 were selected for further characterization. (B) Selection of 20 clones that
did not show cross-reactivity with WT-α-syn. (C) Stability assessment of 5B9, 6H5, and 9G1 over multiple passages and isotype identification for each antibody.
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3.3. Determining the affinity of the antibodies towards pS129-α-syn
Next, we aimed to determine the affinity of our antibodies towards
pS129-α-syn using indirect ELISA. The plate-bound proteins, WT- or
pS129-α-syn, were coated at a constant concentration of 1 μg/ml. Our
mAbs were tested in serial dilutions, starting at a concentration of
10 μg/ml and diluted down to 30 pg/ml. All 3 mAbs, 5B9, 6H5, and
9G1, were found to be highly specific for pS129-α-syn and show
minimal cross-reactivity with the WT-α-syn (Fig. 3A-C). The EC50 va-
lues for 5B9, 6H5, and 9G1 were 1.26 nM, 7.3 nM, and 1.3 nM, re-
spectively (Table 1). This is at least ten thousand folds higher affinity
towards pS129-α-syn than WT-α-syn. We found PS129 to be highly
specific, displaying the highest affinity for pS129-α-syn
(EC50= 0.2 nM; Fig. 3D), whereas ab51253 has an affinity comparable
to our mAbs (EC50= 1.5 nM; Fig. 3E). Syn-1 was included as a control
and showed equal selectivity for both forms of α-syn (EC50= 2.0 nM for
WT-α-syn and EC50= 1.90 for pS129-α-syn; Fig. 3F).
3.4. Evaluating the cross-reactivity of the antibodies with off-target proteins
Antibodies directed to pS129-α-syn are extensively used for mea-
suring the abundance of pathological inclusions and for evaluating
disease progression in experimental models and post-mortem brain tis-
sues of synucleinopathies. Therefore, it is important to validate the
specificity of these antibodies to accurate assessment of pathology.
Given that LBs/GCIs in brain from patients with synucleinopathies are
mostly comprised of aggregated pS129-α-syn species, it was important
Fig. 2. Assessing the purity and specificity of
pS129-α-syn mAbs. (A) 5B9, 6H5, and 9G1 (5
ug) were run on 12 % SDS-PAGE under dena-
turing conditions to assess purity following
protein-G affinity chromatography. Two bands
at 25 KDa and 50 KDa correspond to light and
heavy chains of IgG antibody, respectively. (B)
Western blot demonstrating the specificity of
the antibodies towards pS129-α-syn. Syn-1 was
included as a control. All antibodies were used
at 100 ng/ml.
Fig. 3. Determining the affinity of 5B9, 6H5, and 9G1 towards pS129-α-syn. Using indirect ELISA, WT-α-syn or pS129-α-syn were coated on a 384-well plate then
detected by (A) 5B9 (B) 6H5 (C) 9G1 and the 3 control antibodies: (D) PS129 (E) ab51253 (F) Syn-1 in serial dilutions. Antibody dilution curves were plotted to
estimate the affinity of each antibody. These were used to calculate EC50 of each mAb towards both antigens (Table 1). The assay was performed three times for each
mAb. Error bars are shown, except in the instances where the error bars are shorter than the height of the symbol.
Table 1
Summary of the EC50 for each of our anti- pS129-α-syn mAbs towards WT- or
pS129-α-syn.
mAb EC50 (nM) for
WT α-syn
EC50 (nM) for pS129 α-syn Folds of affinity
5B9 4.0×104 1.26 3.2 × 104
6H5 1.0×104 7.30 1.4 × 104
9G1 2.8×104 1.30 2.1 × 104
PS129 1.3×104 0.26 4.9 × 104
ab51253 1.3×104 0.40 3.3 × 104
Syn 1 2.0 1.90 1.0
The concentration of mAbs required to give 50 % of the maximal binding to
either WT or pS129-α-syn were determined according to regression curves
obtained from indirect ELISA. Folds of affinity were estimated by dividing the
EC50 for WT-α-syn over that of pS129-α-syn. The assay was performed three
times and the representative data are shown.
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to validate that our antibodies recognize pS129-α-syn aggregates.
Moreover, it is not uncommon for antibodies raised against pS129-α-
syn peptides to cross-react with WT-α-syn aggregates [13]. Towards
this aim, we assessed the reactivity of our mAbs towards recombinant
WT- or pS129-α-syn aggregates using slot blot. Our results showed that
all antibodies including ab51253 were able to detect pS129-α-syn ag-
gregates and did not cross-react with WT-α-syn aggregates (Fig. 4A).
Syn-1 was included as a control antibody and reacted equally to both
forms of α-syn.
Next, we aimed to investigate whether our antibodies cross-react
with low-molecular weight neurofilament protein phosphorylated at
serine 473 (68 KDa), a protein which several pS129-α-syn antibodies
cross-react with [4,13]. We performed immunoblotting analyses using
post-mortem brain lysates from the frontal cortices of cases with a
clinical diagnosis of PD. All antibodies, including ab51253, were able to
reliably detect pS129-α-syn. Only one mAb, 9G1, detected a band at
∼70 kDa in all samples, indicating cross-reactivity to pS473 neurofi-
lament protein (68 KDa) (Fig. 4B). This band was not observed with any
of the other antibodies.
3.5. Immunohistochemical staining of human brain tissues
To determine our antibodies ability to recognize disease-relevant
pathological lesions in post-mortem human brain tissue, we obtained
tissues exhibiting relevant pathologies from phenotypically important
regions: substantia nigra from PD cases, amygdala from DLB cases,
entorhinal cortex from mixed DLB/Alzheimer’s disease (AD) and pu-
tamen from MSA cases. We conducted immunohistochemistry using our
three new antibodies as well as PS129 and ab51253. Results showed
that all antibodies were able to reliably stain α-syn pathology in the
substantia nigra (Fig. 5A–E), amygdala (Fig. 5F–J) entorhinal cortex
(Fig. 5K–O) and putamen (Fig. 5P–T) of cases with different synuclei-
nopathies.
Our antibodies labeled the circumference of intracellular LB inclu-
sions in the substantia nigra of a PD case, consistent with the typical
morphology of brainstem-type LBs [15]. In contrast, LBs in entorhinal
cortex of a mixed DLB/AD case and amygdala of a DLB case had a
typical cortical LB morphology of a smaller size and less dense, but
uniformly stained, structure. Neuritic pathology was also observed in
all evaluated regions, both as fine α-syn-immunoreactive threads and
larger swollen neurites. Numerous GCIs were observed in the putamen
of an MSA case. The antibody 9G1, which cross-reacts with pS473
neurofilament, showed more staining of neuronal processes. Although it
labeled α-syn inclusions well in different regions, whether this is really
pS129 α-syn staining, or cross-reactivity with pS473 neurofilament
remains in question.
4. Discussion
In this study, we aimed to address the need for the development of
antibodies specific for pS129-α-syn, a form of the protein that is im-
plicated in synucleinopathies. α-Syn is known to undergo several post-
translational modifications in PD and related disorders, the most
abundant being phosphorylation at serine 129. Various studies ex-
amined the effect of phosphorylation of α-syn at S129 but failed to
reach a consensus as to the role played by this modification [16]. To
gain an insight into the role of pS129-α-syn and to understand the stage
at which phosphorylation takes place, highly specific antibodies are a
pressing unmet need.
Only few antibodies specific for pS129-α-syn are commercially
available and generation of specific antibodies towards pS129-α-syn
continues to be a challenge [11,13], due to their tendency to cross-react
with other proteins. For example, the commercial antibody MJFR13
(Abcam) was reported to exhibit some nonspecific signal and was dis-
qualified from assessing α-syn pathology [13]. Another commercial
antibody, pSer129 (also called 81A; Abcam) was employed in several
studies to assess α-syn pathological inclusions in model systems
[18,19]. However, it was later shown to cross react with low molecular
mass neurofilament protein [14]. This warrants caution as it may have
led to over-representation or false interpretations of α-syn pathology.
Another antibody called pSyn#64 (Wako Chemicals), commonly used
for immunohistochemical staining of α-syn pathology [20], has been
reported to cross-react with unknown nuclear antigens in α-syn knock-
out mice [11]. Nevertheless, a fourth commercial mAb, ab51253 (also
called EP1536Y; Abcam), which is widely used in immunoblotting and
immunohistochemistry, was reported to uniquely and robustly detect α-
syn inclusions [19,21,22]. In a recent study that compared the sensi-
tivity and specificity of these four anti-pS129-α-syn commercial mAbs,
ab51253 was found to exhibit the highest specificity among the
aforementioned mAbs [11], although it has been reported to occa-
sionally stain an unknown high-molecular weight protein that is not α-
syn (∼100 KDa) in immunoblots [11].
The major aim of our study was to generate and thoroughly char-
acterize new mAbs that are highly specific for pS129-α-syn. We
Fig. 4. Assessing cross-reactivity of the antibodies towards off-target proteins. (A) slot blot analyses using recombinant monomeric or aggregates WT-α-syn and
pS129-α-syn (50 ng/slot) in duplicates. Blots were probed with indicated antibodies. (B) Western blot analyses using sequentially extracted urea-soluble brain lysates
from frontal cortices of cases with clinical diagnosis of PD and probed with indicated antibodies. Antibody against neurofilament protein (anti-NFL; Abcam) was used
as a positive control at 1:5000 dilution.
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described the development and extensive characterization of three
monoclonal antibodies specific for pS129-α-syn, in addition to PS129
[14] and ab51253. Using a wide range of biochemical assays, we va-
lidated their specificity and assessed their affinity towards pS129-α-syn.
Generating specific pS129-α-syn antibodies that are not confounded by
reactivity with other off-targets has been a challenge [11,13]. Cross-
reactivity of pS129-α-syn antibodies with neurofilament protein has
been highlighted as a common concern [13]. This is partially due to its
high abundance in brain tissue, as well as the sequence homology be-
tween pS129 epitope of α-syn and pS473 epitope of neurofilament, both
of which are phosphorylated by mutual kinases [13]. To this end, our
study yielded two new mAbs, 5B9 and 6H5, as well as our previously
generated mAb PS129 that do not cross-react with neurofilament pro-
tein. Our other antibody, 9G1, showed cross-reactivity with 68 KDa
pS473 neurofilament protein. Similar to the observations made by other
research groups, we have also confirmed that ab51253 exhibits high
specificity and does not cross-react with neurofilament [11,14]. We
were able to identify two new mAbs (5B9, 6H5) that are specific for
pS129-a-syn and validate PS129 and ab51253 for their usefulness in
assessing pS129-α-syn from brain tissue from different synucleino-
pathies.
Besides the use of pS129-α-syn antibodies as research tools, re-
searchers explored the presence of pS129-α-syn in human biofluids as a
potential biomarker for PD and related synucleinopathies. Several stu-
dies suggested that pS129-α-syn inclusions could differentiate between
synucleinopathy cases. For example, one study demonstrated, using
post-mortem analyses, that pS129-α-syn levels are higher in PD with
dementia and DLB groups compared to PD without dementia, indicating
an association between pS129-α-syn accumulation and dementia [23].
In body fluids, Allsop and colleagues reported that levels of pS129-α-
syn in CSF is substantially higher in MSA compared with other synu-
cleinopathies [17]. These results suggest that levels of pS129-α-syn,
rather than WT-α-syn, might serve as a biomarker to discriminate be-
tween synucleinopathies. It has been reported that pS129-α-syn is ele-
vated in blood or plasma of PD patients [17]. Similar findings were
observed in skin, gastric biopsies, as well as CSF [24,25,14], suggesting
that the presently reported antibodies could offer new opportunities for
the development of promising biomarkers for the diagnosis of synu-
cleinopathies.
In summary, this study demonstrates the generation and extensive
characterization of new mAbs that are highly specific for human pS129-
α-syn and detect pathology in human brain tissue from different sy-
nucleinopathies. Based on our findings and given the variable specifi-
cities for such antibodies, the best approach to tackle the role of
phosphorylated forms of α-syn would be to use several different mAbs
in parallel. Efforts to develop and thoroughly validate new antibodies
are of great importance to facilitate our understanding of α-syn phos-
phorylation in synucleinopathies and potentially aid in biomarker dis-
covery for early diagnosis of these diseases.
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